CVLLY (CellaVision AB) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)

What is CellaVision AB LT-Debt-to-Total-Asset?

CellaVision AB CVLLY +12.06% 69 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CellaVision AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

CellaVision AB's long-term debt to total assets ratio stayed the same from Mar. 2025 (0.01) to Mar. 2026 (0.01).

CellaVision AB (OTCPK:CVLLY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CellaVision AB LT-Debt-to-Total-Asset Related Terms

CellaVision AB LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for CellaVision AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB LT-Debt-to-Total-Asset Chart

CellaVision AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.12

0.07

0.03

0.01

CellaVision AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

69GF Score

CellaVision AB CVLLY

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CellaVision AB LT-Debt-to-Total-Asset Calculation

CellaVision AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	1.288	/	117.812
	=	0.01

CellaVision AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	1.112	/	121.794
	=	0.01

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.01 mean?

CellaVision AB (CVLLY) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CellaVision AB and its competitors.

Is CellaVision AB's LT-Debt-to-Total-Asset too high?

CellaVision AB's current LT-Debt-to-Total-Asset is 0.01. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does CellaVision AB's LT-Debt-to-Total-Asset compare to ABT and SYK?

CellaVision AB's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CellaVision AB and its competitors. CellaVision AB's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CellaVision AB stock overvalued right now?

Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellaVision AB (CVLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued. The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48. GuruFocus considers CellaVision AB to be Significantly Undervalued.

Key valuation signals for CVLLY:

LT-Debt-to-Total-Asset: 0.01
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellaVision AB Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OSTO:DVYSR OSTO:BICO OSTO:PAX OSTO:CRAD B OSTO:SEDANA OSTO:EPIS B OSTO:SEZI OSTO:BACTI B OSTO:SCIB OSTO:OSSD ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges CLVSF:USA CEVI:Sweden 0MR5:UK C26:Germany

Address Mobilvagen 12, Lund, SWE, 22362

Website https://www.cellavision.com

CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.

69GF Score

Get the complete analysis for CVLLY

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.06

Price

$12.48

GF Value

View CVLLY Analysis

See LT-Debt-to-Total-Asset data for all stocks →